Speaker Profile
Ph.D., Vice President, Business Development and Customer Solutions, biomodal
Biography
Dr. Jennifer Stone is a commercial life sciences executive specializing in building markets, high performing international teams and sustainable topline growth. She joined biomodal in 2023 to build out and lead the business development, sales and customer solutions teams to deliver on the companys commercial growth objectives. Dr. Stone has over two decades of experience in the omics space. Before joining biomodal, Dr. Stone worked at PacBio as part of the leadership team that led to transformative change within that organization and ultimately the launch of the game changing Revio long read sequencing platform. She also held several commercial roles at Illumina. Dr. Stone has focused her career on the intersection of technology and precision health, specifically with early mid stage technologies as they cross the chasm into translational and applied use.
Talk
Ultra‑sensitive ctDNA detection for ECD/MRD
biomodal’s 6-base sequencing enables ultra-high sensitivity ctDNA detection by expanding feature selection for detection from one-dimensional DNA variants to multi-dimensional genetic variant, methylation, hydroxymethylation, and fragmentomics features - greatly expanding the power of precision medicine to detect ctDNA in early cancer and minimal residual disease.
Clinical Dx Showcase:
biomodal
biomodal is an omics-based life sciences technology and analytics company delivering products that reveal the dynamism of biology. Our duet multiomics solution evoC generates rich epigenetic insight from a single, low-input DNA library without harsh chemistry or complex bioinformatics. With single‑base, phased sequencing, we unify genetic and epigenetic data in one workflow, advancing research in cancer, neurodegenerative disease, and ageing.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
